Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XG005 in Healthy Volunteers
NCT04067947Phase 1Completed
- Sponsor
- Xgene Pharmaceutical Inc.
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing XG005 with Placebo (2 arms). Primary endpoint: Adverse Event related to XG005. Started Jul 2019; status: completed.
02
Drugs
pregabalin naproxencarbil
03
Conditions
pain
Beyond the preview
Go deeper on NCT04067947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067947.